Neuland Laboratories Limited (NEULANDLAB.NS)
INR 11154.3
(-2.17%)
INR 11154.3
(-2.17%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.92 Billion INR | -70.66% |
| 2022 | 3.58 Billion INR | 29.69% |
| 2021 | 2.76 Billion INR | 7.94% |
| 2020 | 2.55 Billion INR | 23.27% |
| 2019 | 2.07 Billion INR | 25.86% |
| 2018 | 1.64 Billion INR | 0.67% |
| 2017 | 1.63 Billion INR | -6.82% |
| 2016 | 1.75 Billion INR | 36.32% |
| 2015 | 1.29 Billion INR | 11.1% |
| 2014 | 1.16 Billion INR | 0.41% |
| 2013 | 1.15 Billion INR | 16.89% |
| 2012 | 989.43 Million INR | 7.24% |
| 2011 | 922.67 Million INR | 90.99% |
| 2010 | 483.09 Million INR | 3.12% |
| 2009 | 468.47 Million INR | 21.68% |
| 2008 | 384.99 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 300.66 Million INR | -15.51% |
| 2023 Q2 | 1.03 Billion INR | 7.43% |
| 2023 Q1 | 960.54 Million INR | 4.38% |
| 2023 Q4 | 355.84 Million INR | -67.09% |
| 2023 FY | 1.05 Billion INR | -70.66% |
| 2023 Q3 | 1.08 Billion INR | 4.77% |
| 2022 Q4 | 920.25 Million INR | 3.32% |
| 2022 Q2 | 913.78 Million INR | 6.41% |
| 2022 FY | 3.58 Billion INR | 29.69% |
| 2022 Q1 | 858.74 Million INR | 75.23% |
| 2022 Q3 | 890.68 Million INR | -2.53% |
| 2021 Q1 | 702.08 Million INR | -2.04% |
| 2021 FY | 2.76 Billion INR | 7.94% |
| 2021 Q3 | 768.18 Million INR | -4.31% |
| 2021 Q4 | 490.06 Million INR | -36.2% |
| 2021 Q2 | 802.76 Million INR | 14.34% |
| 2020 Q2 | 619.01 Million INR | 10.79% |
| 2020 FY | 2.55 Billion INR | 23.27% |
| 2020 Q4 | 716.7 Million INR | 7.7% |
| 2020 Q3 | 665.43 Million INR | 7.5% |
| 2020 Q1 | 558.74 Million INR | 16.19% |
| 2019 Q3 | 539.02 Million INR | -3.0% |
| 2019 FY | 2.07 Billion INR | 25.86% |
| 2019 Q4 | 480.89 Million INR | -10.79% |
| 2019 Q2 | 555.69 Million INR | 10.9% |
| 2019 Q1 | 501.08 Million INR | 112.37% |
| 2018 Q3 | 501.21 Million INR | 9.6% |
| 2018 Q2 | 457.33 Million INR | 0.41% |
| 2018 Q1 | 455.48 Million INR | 0.0% |
| 2018 FY | 1.64 Billion INR | 0.67% |
| 2018 Q4 | 235.94 Million INR | -52.93% |
| 2017 FY | 1.63 Billion INR | -6.82% |
| 2016 Q4 | 364.19 Million INR | -34.43% |
| 2016 Q3 | 555.41 Million INR | 68.77% |
| 2016 Q2 | 329.1 Million INR | -9.45% |
| 2016 FY | 1.75 Billion INR | 36.32% |
| 2016 Q1 | 363.43 Million INR | 0.0% |
| 2015 FY | 1.29 Billion INR | 11.1% |
| 2014 FY | 1.16 Billion INR | 0.41% |
| 2013 FY | 1.15 Billion INR | 16.89% |
| 2012 FY | 989.43 Million INR | 7.24% |
| 2011 FY | 922.67 Million INR | 90.99% |
| 2010 FY | 483.09 Million INR | 3.12% |
| 2009 FY | 468.47 Million INR | 21.68% |
| 2008 FY | 384.99 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -20513.143% |
| Aarti Drugs Limited | 1.16 Billion INR | -150.946% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 4.705% |
| Ajanta Pharma Limited | 30.46 Billion INR | 90.383% |
| Alembic Limited | 872.45 Million INR | -235.804% |
| Alkem Laboratories Limited | 32.83 Billion INR | 91.077% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 81.539% |
| AstraZeneca Pharma India Limited | 2.47 Billion INR | -18.445% |
| Bal Pharma Limited | 555.62 Million INR | -427.287% |
| Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -42858.152% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -106.433% |
| Brooks Laboratories Limited | 51.18 Million INR | -5624.396% |
| Bafna Pharmaceuticals Limited | 455.58 Million INR | -543.073% |
| Caplin Point Laboratories Limited | 2.17 Billion INR | -34.732% |
| Divi's Laboratories Limited | 14.17 Billion INR | 79.324% |
| Eris Lifesciences Limited | 4.94 Billion INR | 40.729% |
| Granules India Limited | 10.31 Billion INR | 71.591% |
| Ind-Swift Limited | 946.56 Million INR | -209.513% |
| Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | -568.053% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 80.194% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 79.731% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -610.367% |
| Medicamen Biotech Limited | 335.16 Million INR | -774.115% |
| Medico Remedies Limited | 59.67 Million INR | -4809.503% |
| Wockhardt Limited | 8.48 Billion INR | 65.451% |
| Orchid Pharma Limited | 800.77 Million INR | -265.866% |
| RPG Life Sciences Limited | 1.63 Billion INR | -79.135% |
| Shilpa Medicare Limited | 3.33 Billion INR | 12.13% |
| Sigachi Industries Limited | 579.88 Million INR | -405.227% |
| Solara Active Pharma Sciences Limited | 2.55 Billion INR | -14.708% |
| Unichem Laboratories Limited | 6.72 Billion INR | 56.441% |
| Vaishali Pharma Limited | 84.02 Million INR | -3386.589% |
| Wanbury Limited | 978.96 Million INR | -199.269% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 97.66% |
| FDC Limited | 3.49 Billion INR | 16.287% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | -39.909% |
| Bajaj HealthCare Limited | 985.34 Million INR | -197.332% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 96.944% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 74.832% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -37.923% |
| Laurus Labs Limited | 11.9 Billion INR | 75.401% |
| Mangalam Drugs & Organics Limited | 162.22 Million INR | -1705.943% |
| Nectar Lifesciences Limited | 932.7 Million INR | -214.115% |
| Par Drugs and Chemicals Limited | 58.28 Million INR | -4926.326% |
| Hester Biosciences Limited | 908.84 Million INR | -222.361% |
| Ipca Laboratories Limited | 18.98 Billion INR | 84.57% |
| Venus Remedies Limited | 1.91 Billion INR | -52.887% |
| ZIM Laboratories Limited | 1.01 Billion INR | -189.198% |
| Aurobindo Pharma Limited | 55.65 Billion INR | 94.736% |
| Morepen Laboratories Limited | 1.98 Billion INR | -47.412% |
| Sequent Scientific Limited | 2.9 Billion INR | -0.963% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -108.852% |
| Valiant Laboratories Limited | 138.02 Million INR | -2022.558% |
| Windlas Biotech Limited | 1 Billion INR | -191.08% |
| Hikal Limited | 4.46 Billion INR | 34.367% |
| Innova Captab Limited | 931.03 Million INR | -214.678% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 2.192% |
| Themis Medicare Limited | 1.12 Billion INR | -160.237% |
| IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | -33.11% |
| Mankind Pharma Limited | 29.27 Billion INR | 89.992% |
| Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 93.76% |
| Sakar Healthcare Limited | 204.07 Million INR | -1335.594% |
| Albert David Limited | 1.02 Billion INR | -185.509% |
| Lupin Limited | 125.09 Billion INR | 97.658% |
| Gufic Biosciences Limited | 1.18 Billion INR | -146.905% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 98.1% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -172.741% |
| Syncom Formulations (India) Limited | 345.63 Million INR | -747.646% |
| Piramal Enterprises Limited | 63.65 Billion INR | 95.397% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 86.324% |
| NATCO Pharma Limited | 10.05 Billion INR | 70.871% |
| Suven Life Sciences Limited | 109.75 Million INR | -2569.472% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -6247.487% |
| Strides Pharma Science Limited | 9.16 Billion INR | 68.024% |
| Indoco Remedies Limited | 12.06 Billion INR | 75.709% |
| Alpa Laboratories Limited | 127.38 Million INR | -2200.005% |
| Lasa Supergenerics Limited | 291.17 Million INR | -906.184% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 4.779% |